Update in immunomodulatory drug therapy for myasthenia gravis / 中华实用儿科临床杂志

ABSTRACT

Myasthenia gravis (MG) is an acquired autoimmune neuromuscular junction disease mediated primarily by anti-acetylcholine receptor antibody.Muscle-specific receptor tyrosine kinase antibody, low density lipoprotein receptor-associated protein 4 antibody and ranine receptor can also reduce the stability of acetylcholine receptors in the postsynaptic membrane and cause disease.The treatment of myasthenia gravis mainly includes symptomatic therapy, immunosuppressive therapy, immunoregulation and thymotomy.Immunosuppressive therapy is the main treatment of MG, but the long-term use of glucocorticoid (a hormone steroid) or a nonsteroidal immunosuppressant can bring about unwanted side effects and adverse events.To solve this problem, research progress of immunosuppressive drugs for treating MG was summarized in this paper.This article aims at finding the right treatment plan and explore the application value of new biological agents in MG treatment.